| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5894d694d4a784d601f503d79e518f2d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2019-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a86f969571893e7d4a5a13cbd37a056f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_532eb1ba5cc151e8af398c72f5d14ce7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9b056d6d7c75a338f5bcfe376375d65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fff3abd575dc7c0df356a956ee3d38c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e63207db23f7799317bb5a3415f8e019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7326db308e8f9851aa26f91ae666e05f |
| publicationDate |
2019-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201945401-A |
| titleOfInvention |
Ways to reduce cardiovascular risk |
| abstract |
The invention provides methods for treating diseases and disorders associated with elevated lipid and lipoprotein content. The method of the invention comprises administering a pharmaceutical composition comprising a PCSK9 inhibitor to a patient at high cardiovascular risk. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, such as an exemplary antibody referred to herein as mAb316P or alizumab. The method of the present invention can be used to treat patients with high cardiovascular risk with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by the maximum tolerated dose of statin therapy. In particular, the method of the present invention can be used to reduce cardiovascular risk and reduce atherosclerotic lipids in patients at high cardiovascular risk despite administering the maximum tolerated dose of statin therapy within 12 months after an acute coronary syndrome event. protein. |
| priorityDate |
2018-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |